Woolsey Pharmaceuticals Announces New ALS Patent Claims
Woolsey Pharmaceuticals is taking significant strides in the field of neurodegenerative diseases, particularly in the treatment of ALS, or amyotrophic lateral sclerosis. With the U.S. Patent and Trademark Office (USPTO) granting additional patent claims for BRAVYL (oral fasudil), there's renewed hope for those affected by this challenging condition.
The Importance of New Patent Claims
These patented claims are pivotal as they specifically address treatment methodologies for various categories of ALS, as established by the El Escorial Revised ALS diagnostic criteria. This encompasses possible to definite ALS cases, further fortified by the inclusion of neurofilament light (NfL) reduction in treatment outcomes.
Clinical Findings with BRAVYL
Woolsey's REAL study has demonstrated promising results, showcasing a reduction in NfL levels by 15% from baseline to six months, with significant statistical relevance (p=0.0006) at a dosage of 180mg/day. Anticipation is building as data from the higher dosage cohort of 300 mg/day is expected soon.
Existing Patent Portfolio
Woolsey Pharmaceuticals’ commitment to advancing ALS treatment is further exemplified through its diverse patent portfolio, which already boasts several key patents. These include:
- US Patent No. 11,779,588, which focuses on treating sporadic ALS;
- US Patent No. 12,128,053, covering treatments using a proprietary dysphagia-friendly formulation;
- US Patent Nos. 11,944,633 and 12,115,167, relating to several formulations that improve the swallowing ability of patients undergoing treatment.
The Mechanism of Action of BRAVYL
At its core, BRAVYL functions as a Rho-kinase inhibitor. Early studies, both preclinical and clinical, suggest that it effectively targets cellular processes that could lead to neuronal injury and loss. This innovative approach might help in reducing the death of motor neurons, which is crucial in the context of ALS treatment.
Quotes from Leadership
Sven Jacobson, the Chief Executive Officer of Woolsey Pharmaceuticals, described these patent claims as essential assets within a larger family of 36 patents. He emphasized that these claims reinforce their proprietary position and innovative approach regarding BRAVYL for ALS treatment, especially since they complement the existing Orphan Drug Designations for ALS in both the U.S. and European markets.
Understanding ALS
ALS is a devastating condition marked by the degeneration of motor neurons, leading to severe physical disability and eventually death. Patients typically only survive from two to five years post-diagnosis, making advancements in treatment protocols crucial. The ability to slow disease progression and improve quality of life is paramount.
About Woolsey Pharmaceuticals
Based in New York, Woolsey Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to the development of treatments for ALS and other neurodegenerative disorders. Their focus on groundbreaking therapies aims to provide hope and healing to individuals facing these life-altering challenges.
Frequently Asked Questions
What is BRAVYL and how does it work?
BRAVYL (oral fasudil) is an investigational drug that acts as a Rho-kinase inhibitor, targeting cellular mechanisms linked to motor neuron damage in ALS patients.
What recent developments has Woolsey Pharmaceuticals achieved?
Woolsey Pharmaceuticals has secured new patent claims for BRAVYL, reinforcing their position in ALS treatment and focusing on neurofilament light reduction.
What types of ALS does the new patent cover?
The patent addresses treatment for possible, probable laboratory-supported, probable, or definite ALS cases according to established diagnostic criteria.
What are the outcomes from the REAL study?
The REAL study indicated a significant reduction in neurofilament light levels by 15% after six months of treatment with BRAVYL at a 180mg/day dosage.
Why is ALS treatment so important?
ALS leads to rapid declines in health and quality of life, making effective treatments critical for extending survival and improving daily living for affected individuals.
